Bionomics Ltd
Tuesday, February 27, 2024
Plymouth
CNS/Neurological
Bionomics, a publicly listed clinical late-stage company focused on addressing unmet needs in CNS. We are developing BNC-210, a Ph3-Ready First- and-Best-in-Class α-7 Nicotinic Receptor for the Treatment of Neuropsychiatric Disorders. BNC-210 has received Fast Trak designation for Post-Traumatic Stress Disorder (PTSD) and Social Anxiety Disorder (SAD).
Country
Australia
Website
https://www.bionomics.com.au/
CEO/Top Company Official
Spyros Papapetropoulos
Lead Product in Development
BNC-210
Development Phase of Primary Product
Phase III
Number Of Unlicensed Products
1
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}